Alzheimer's Research Notes and Discovery
Inventory item: 8457 | SKU: 2038 | Line: Blueprints
Page: https://cri-one.com/11-alzheimers-research-notes-discovery.html
Owner and author: Christopher Gabriel Brown (CRI-ONE)
Record date: 8 October 2026
Approved public wording item: medical and regulatory wording follows D:/special/_inventory/descriptions-public/8457.md
1. The Record in Brief
Alzheimer's Research Notes and Discovery is a research and discovery IP record by Christopher Gabriel Brown: an Alchemy Data V2 search of 16 element combinations against Alzheimer's disease mechanisms that returned 14 ranked research candidates, carried through to metal-amino acid coordination complexes, synthesis conditions, four formulations and an evidence-graded assessment (Evidence 10, 12). Its earliest dated disclosure is Invent Depositions, ISBN 978-1-979767-89-7, first shipped 24 November 2017, deposition #769 on printed page 181, joined by 2017 catalog depositions #373, #133 and #486 (Evidence 1 to 4). Its USPTO anchor is U.S. Application No. 19/441,975, received 7 January 2026, Confirmation No. [redacted], pending, joined by the pending umbrella applications 19/540,453 and 19/693,405 (Evidence 5 to 7). Its first public offering is the cri-one.com open-research listing created 12 March 2026; its current item page and card Buy button went live on 8 October 2026 (Evidence 13, 14). Its text, drawings, code and data carry the notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (Evidence 8).
2. Proprietary - What Is Owned and How It Is Held
The source package holds 63 files in six subfolders (count of 8 October 2026; its own table of contents of 6 October 2026 lists 61 files before the two table-of-contents files). The file families are:
- Code and data: the 451-line Python discovery script, its configuration module, the 14-record discovery JSON and the H2O discovery report JSON (Evidence 10, 11).
- Findings: five reports, including the V1, V2 and V3 known-properties passes.
- Patent papers: the application text with 20 claims and four figures, the claims summary, a filing checklist, the USPTO notice record and two response documents (Evidence 9).
- Drawings: FIG. 1 to FIG. 4 in SVG and PDF (eight files), four top-level SVG drawings and two 11 x 17 charts.
- Pre-IND planning set: eight documents dated 3 September 2026.
- Documentation: README, METHODOLOGY, SAFETY_DISCLAIMER, IP_NOTICE, LICENSE, MANIFEST.json, CITATION.cff, CHANGELOG, web pages, the package archive and nine sales and delivery documents.
A second copy of 38 files under D:/special/45-fda-rebuttles-and-adwork/ carries a byte-identical LICENSE and package archive and adds five rebuttal and positioning documents (FDA rebuttal, rebuttal notes, red-team and steelman proofs, essay).
Ownership. The LICENSE states that the Work is "the exclusive property of Christopher Gabriel Brown." (Evidence 8). He is the first named inventor and the filer on the 19/441,975 receipt (Evidence 5). No assignment is of record.
What a buyer receives. The LICENSE reads "NO LICENSE IS GRANTED." and reserves copying, distribution and transfer to the copyright holder (Evidence 8). The purchase term at https://cri-one.com/terms reads "When you buy, you buy the use of that blueprint only." and is a required field at Stripe checkout ("I agree: when I buy, I buy the use of that blueprint only.", D:/special/crione-static/delivery-v2/make_payment_links.py); the item page repeats it beside the Buy button (Evidence 14).
Secrecy measures of record (18 U.S.C. 1839(3)). Full packages go only to paying buyers; the item page states "Your files arrive by email after payment." (Evidence 14). The mutual NDA is published at https://cri-one.com/nda/ and its full text travels in every delivery e-mail (D:/special/crione-static/delivery-v2/deliver.py). The public item page carries only the description. The research core went public through the open-research listing of 12 March 2026 and is held by copyright and by its publication date; the pre-IND set, the prosecution papers and the formal figure set added since then travel only inside the delivered package.
3. First Art - The Earliest Dated Disclosure
| Date | Record | What it discloses | Source |
|---|---|---|---|
| 2017 (entry mark) | 2017 catalog, deposition #373 | A study by toxic and valence testing naming diseases like Alzheimer's | Evidence 1 (line 1061), 2 |
| 2017 (entry mark) | 2017 catalog, deposition #133 | Diagnosing receptor-site changes in the central nervous system | Evidence 1 (line 369), 2 |
| 2017 (entry mark) | 2017 catalog, deposition #486 | Computational predictive alchemy studies, origin of Alchemy Data | Evidence 1 (line 1186), 2 |
| 24 Nov 2017 | Invent Depositions, deposition #769, printed page 181 | The proper chemicals in the brain without poisoning other organs | Evidence 3, 4 |
| 7 Jan 2026 | USPTO receipt, U.S. Application No. 19/441,975 | Zinc-amino acid complexes, Alzheimer's subject; 21-page application body | Evidence 5 |
| 12 Mar 2026 | Listing "Open Research: Alzheimers Mechanism Analysis" with package download | 14 compounds, 12 mechanisms, formulation chart, V3 report, Python scripts | Evidence 13 |
Deposition anchors (D:/Rebuttals/_registers/DEPOSITIONS_A.json, confirmed against the master IP register, Evidence 1):
- Deposition #373, direct match, 2017 catalog, entry marked copyright © 2017 chris g brown: "by way of toxic and valance testing to include but not limited to cancer and diseases like alzheimer's and substance abuse cessation aids"
- Deposition #769, printed book page 181: "chemical balance relation goal is the chance to achieve the proper chemicals in the brain or an organ to make it work better and function regulatory like while not poisoning the other organs"
- Deposition #133, 2017 catalog, marked copyright © 2017 chris g brown: "diagnose changes at dopa mine serotonin adrenaline and histamine receptor sites in the central nervous system"
- Deposition #486, 2017 catalog: "computational predictive plasma sorting lapidary alchemy studies"
The master IP register, D:/special/82-alchemy-calc-two/1 light trigger.txt (1,769 lines), is the source of record; its copies in 50-pcie8-standard and 43-redaction-pen carry the same SHA-256 (Evidence 1).
Defensive-publication effect. Under 35 U.S.C. 102(a)(1), a printed publication or other public availability before a filing date is prior art against that filing. The 2017 book and catalog entries stand against every later filer on the subject matter they disclose. The listing of 12 March 2026 and the item page of 8 October 2026 stand against every later filer on the candidates, mechanism map, evidence grading, synthesis conditions, formulations and scripts they publish. A challenger must produce a dated record earlier than 24 November 2017 disclosing the same research line, or earlier than 7 January 2026 disclosing an elemental-probability search mapped to Alzheimer's mechanisms together with the metal-amino acid coordination complexes it selects. None is of record.
Prior Art Considered and Distinguished
Sources: the site provenance file for SKU 2038 (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json; PRIOR_ART_REGISTER.json, by_product 8457), the package's literature and trial tables (Evidence 12), and the owner's brain-chemistry filing analysis (D:/special/22-brain-chemistry/patent_application/FILING_CHECKLIST_AND_IP_ANALYSIS.md). Each is distinguished on the product's documented structure: an elemental mechanism-overlap search carried through to amino acid coordination complexes for Alzheimer's research.
| Reference | Title as recorded | Distinction |
|---|---|---|
| US 4,775,876 | Photon recycling light emitting diode | LED photon recycling; a different field |
| US 2012/0305059 A1 | Photon recycling in an optoelectronic device | Optoelectronics; a different field |
| US 2010/0183919 A1 | Quantum dot ultracapacitor and electron battery | Energy storage; a different field |
| US 6,175,719 B1 | Multi-Spot-Beam Satellite | Satellite payload; a different field |
| US 7,418,236 B2 | Extraterrestrial Communications Systems | Satellite communications; a different field |
| US 11,258,379 B2 | Quantum Noise Power Devices | Energy harvesting; a different field |
| US 8,734,855 B2 | Slow release metal amino acid chelates | Owner's filing analysis: lists "additional metal ions" generically and does not claim the mechanism-based rationale; the complexes of this package are selected by an Alzheimer's mechanism search (Evidence 10, 12) |
The package also records the published metal-biology literature and trials as context, with their titles as the package writes them (Evidence 12):
| Literature | Title as recorded | Distinction |
|---|---|---|
| Cherny RA et al. (2001), Neuron 30:665-676 | Copper-zinc chelator inhibits beta-amyloid accumulation | A chelator; the package claims coordination complexes and records chelation as context |
| Lannfelt L et al. (2008), Lancet Neurol 7:779-786 | PBT2 targeting Aβ as modifying therapy for AD | A metal protein attenuating compound, a different class; recorded as trial context |
| Ayton S et al. (2024), JAMA Neurology | Deferiprone in Alzheimer Disease: A Randomized Clinical Trial | An iron chelator trial; the package's direction is redistribution and functional support |
4. First to File - The USPTO Record
| U.S. Application | Filed | Status of record | What it covers for this product | Source |
|---|---|---|---|---|
| 19/441,975 | 7 Jan 2026 | Pending; reply with fees and extension recorded as filed 17 Sep 2026 | The package subject matter: coordination complexes, compositions, synthesis and use claims (package application text) | Evidence 5, 9 |
| 19/540,453 | 13 Feb 2026 | Pending; Filing Receipt mailed 27 Jul 2026 | Umbrella; its title names the disease-discovery systems (Projects 10 to 13) | Evidence 6 |
| 19/693,405 | 30 May 2026 | Pending; Filing Receipt mailed 25 Jun 2026 | Flagship umbrella; Project 11 is entry 11 of the as-filed catalog | Evidence 7; D:/manager/work/2 current_work_catalog.txt |
Under the AIA, every application is dated by its own effective filing date. The USPTO Electronic Acknowledgement Receipt for 19/441,975 records receipt on 7 January 2026 at 09:50:07 ET, Confirmation No. [redacted], Patent Center No. 73872206, a utility nonprovisional under 35 U.S.C. 111(a) (Evidence 5; legacy file name, contents recorded as the 19/441,975 receipt in USPTO_REGISTER.json). The umbrella receipts record 13 February 2026, Confirmation No. [redacted], and 30 May 2026, Confirmation No. [redacted] (Evidence 6, 7). No benefit claim is of record for 19/441,975 or 19/540,453, and the 19/693,405 Filing Receipt mailed 25 June 2026 lists no domestic benefit claim (USPTO_REGISTER.json); each stands on its own filing date. A challenger asserting an earlier filing must produce an application with an effective filing date before 7 January 2026 claiming the same zinc-, copper-, multi-metal and mineral-enhanced amino acid coordination complexes directed to Alzheimer's disease. None is of record.
Marking line: Patent pending - U.S. Application Nos. 19/441,975, 19/540,453 and 19/693,405.
5. First to Market - The Dated Public Offering
| Date | Event | Where | Source |
|---|---|---|---|
| 12 Mar 2026 | Listing "Open Research: Alzheimers Mechanism Analysis" (SKU RESEARCH-11-ALZHEIMERS) created with package download; online in the 8 Apr 2026 export | cri-one.com, old store | Evidence 13 |
| 19 Apr 2026 | Provenance Record ledger lists the listing as first posted | cri-one.com/store/ | D:/manager/first-to-market/first-to-market-LEDGER.csv |
| 31 Aug 2026 | Blueprint record SKU 2038 created in Enterprise blueprints | cri-one.com, old store | D:/manager/_store/export_catalog_product_20260831_201548.csv |
| 1 Sep 2026 | Record re-created; kept in the 7 Sep 2026 export | cri-one.com, old store | D:/manager/export_catalog_product_20260907_110415.csv |
| 4 Sep 2026 | Delivery file of record dated | Delivery copies | D:/special/crione-static/delivery-v2/product_deliverables.csv |
| 8 Oct 2026, 03:55 UTC | First new-site email campaign to US company prospects (portfolio-wide) | cri-one.com mail | D:/special/_mailer/campaigns/new-site-2026-10/campaign.json |
| 8 Oct 2026 | Item page published on the new static site | cri-one.com/inventory/item-8457/ | Evidence 14 |
| 8 Oct 2026, 05:06 UTC | Stripe card Payment Link (created 04:55:57Z) public as the Buy button | Item page | Evidence 14; FIRST_TO_MARKET_REGISTER.json |
6. Copyright
Notice of record: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (package LICENSE, byte-identical in both copies, Evidence 8). The item page carries "© 2026 Christopher Gabriel Brown. All rights reserved." (Evidence 14).
Works covered. Text: README, methodology, safety statement, the five findings reports, the application text, the claims summary and the pre-IND drafts. Drawings: FIG. 1 to FIG. 4 in SVG and PDF, four SVG drawings and two 11 x 17 charts. Code: the discovery script and its configuration. Data: the two discovery JSON files, as compilations. Copyright protects this expression; the compounds, methods and structures are held by the patent filings and by confidentiality (17 U.S.C. 102(b)).
Registrations of record. The owner's corpus is anchored at the Copyright Office by 20 registrations marked verified in D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json, effective 1 October 2010 to 15 March 2026, among them TX 8-396-625 (abstract, 9 May 2017) and TX 9-504-677 (estimated, 6 May 2025). The 2026 package is protected from fixation (17 U.S.C. 102(a)); registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)), and a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).
Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the concept, the numbered depositions written by Christopher Gabriel Brown, and his selection, arrangement and direction of this package, including the V2 and V3 evidence-graded reviews of the computational output against the peer-reviewed literature (Evidence 12).
Notice practice. The notice sits in the package LICENSE, the sales product card and the item page; the 2017 depositions carry their own marks (Evidence 1, 2). The notice defeats an innocent-infringer defense (17 U.S.C. 401(d)).
7. Firm Rebuttals
Challenge 1 - "Metal biology in Alzheimer's disease is decades old; nothing here is original."
Rebuttal. The package cites the published biology by PMID, including Bush et al. 1994 (PMID 7985291) and Cherny et al. 2001 (PMID 11430801) (Evidence 12); the record owns what is new. The research line is dated to 2017 by depositions #373, #133, #486 and #769 (Evidence 1 to 3). The claimed complexes are dated by the 7 January 2026 filing (Evidence 5), and the full combination, from the elemental-probability search to synthesis conditions and four formulations, was published through the listing of 12 March 2026 (Evidence 12, 13). A challenger must produce a dated record earlier than 7 January 2026 disclosing an elemental-probability search mapped to Alzheimer's mechanisms together with the complexes it selects. None is of record.
Challenge 2 - "Someone filed first."
Rebuttal. Under first-inventor-to-file, the challenger must produce an application with an effective filing date before 7 January 2026 claiming the same amino acid coordination complexes directed to Alzheimer's disease. None is of record. Any later filer meets the 2017 depositions and the listing of 12 March 2026 as prior art under 35 U.S.C. 102(a)(1).
Challenge 3 - "It is only pending, so there is nothing to respect."
Rebuttal. The owner holds U.S. Application No. 19/441,975, filed and pending, with two pending umbrella applications (Section 4); "patent pending" marking is correct while an application is pending (35 U.S.C. 292). The package is also held by copyright, by the purchase term and NDA, and by a dated record that stands as prior art against later filers.
Challenge 4 - "It was published, so it is free to use."
Rebuttal. Publication is disclosure, not a transfer of ownership. The listing of 12 March 2026 followed the 7 January 2026 filing, so it does not precede 19/441,975 and cannot stand against it under 35 U.S.C. 102(a)(1); against every later filer it stands as dated prior art. The open-research notice issued with that archive is a permission for educational and research use, sharing and building upon that research, with credit to the author; it assigns no copyright and names no patent license (Evidence 16). Copyright in the expression stays with Christopher Gabriel Brown after publication. The material added since, the pre-IND set, the prosecution papers and the formal FIG. 1 to FIG. 4 figure set, is held under the package LICENSE of 2 May 2026, which reads "NO LICENSE IS GRANTED." (Evidence 8), and a buyer receives the use of that blueprint only (Evidence 14).
Challenge 5 - "AI made it, so there is no copyright."
Rebuttal. The protectable core is human-authored: the 2017 depositions written by Christopher Gabriel Brown and printed under ISBN 978-1-979767-89-7, and his selection, coordination and arrangement of this 63-file package and of the reviews it records (Evidence 1 to 4, 12). Copyright Office guidance of March 2023 protects exactly that human-authored expression and arrangement.
Challenge 6 - "The dates can be faked."
Rebuttal. The dates rest on third-party records. ISBN 978-1-979767-89-7 identifies the CreateSpace edition first shipped 24 November 2017 per the CreateSpace label on the back-cover scan (Evidence 4); Buy Invent 2020 carries ISBN 979-8634479828 and Amazon ASIN B086PVSKFM (COPYRIGHT_REGISTER.json). Internet Archive first captures date crioner.com to 23 January 2010, cri-one.com to 28 January 2011 and buyinvent.com to 5 March 2014 (Evidence 15). The USPTO stamped 19/441,975 at 09:50:07 ET on 7 January 2026 (Evidence 5); Stripe stamped the Payment Link 2026-10-08T04:55:57Z (FIRST_TO_MARKET_REGISTER.json). The first-to-market evidence file carries SHA-256 0d73df2a61db556d, recomputed on 8 October 2026 and matching, and the 16 files of this record are fingerprinted in D:/Rebuttals/_evidence/8457.sha256.
Challenge 7 - "An Alzheimer's application with treatment claims is an unapproved medical claim."
Rebuttal. This is a research and discovery IP record and makes no treatment claim. Patent claims define the scope of the right sought at the USPTO; they are not a representation that a compound works. The approved public description states the research status as "Computational research findings — not clinically validated treatments" and calls the method "A starting point for further research, not drug discovery or clinical validation." (Evidence 12). The package records the clioquinol, PBT2 and deferiprone trials as context and sets out the development pathway from synthesis through cell, animal, safety and clinical studies to FDA approval (Evidence 12).
Challenge 8 - "The scores and probabilities prove nothing."
Rebuttal. The figures are defined by the owner's methodology and recorded exactly. The approved description states: "Discovery scores reflect database coverage and mechanism overlap, NOT therapeutic probability." and that probability values are mathematical calculations from the Alchemy system, not clinical success rates (Evidence 12). Its statistics read: 16 element combinations tested; 14 research candidates identified; top score 50.5/100 (C-H-O-N); average probability 0.002569. The discovery JSON records C-H-O-N at discovery_score 50.5046961402217 and probability 0.010093922804433985 (Evidence 10).
Challenge 9 - "It is just an idea."
Rebuttal. The package is concrete work product: a 451-line Python discovery script, two discovery JSON files, five findings reports, the 20-claim application text, twelve drawing files, two 11 x 17 charts, eight pre-IND documents and the USPTO prosecution papers (Section 2; Evidence 9 to 11).
8. Evidence Index
| # | File | SHA-256 (first 16 hex) | What it proves |
|---|---|---|---|
| 1 | D:/special/82-alchemy-calc-two/1 light trigger.txt | 2dcb359de3f1b56d | Master IP register; depositions #133, #373, #486, #769 |
| 2 | D:/manager/book-ocr-2017-invent-depositions/entries-clean.csv | ad3b87e885814dbb | 2017 catalog entries with 2017 marks |
| 3 | D:/manager/book-ocr-2017-invent-depositions/entries-index.csv | 9e72c4638df2ca6e | Deposition #769 on printed page 181 |
| 4 | D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md | 2abd4f4b4881f8f6 | ISBN, CreateSpace, first shipped 24 Nov 2017 |
| 5 | D:/USPTO Responses/Receipts/N417diabetes.pdf | a2aa6ac673f1873f | 19/441,975 receipt, 7 Jan 2026, Confirmation [redacted] |
| 6 | D:/USPTO Responses/work/N417.PYMT.pdf | db26b63fe8f25e08 | 19/540,453 receipt, 13 Feb 2026 |
| 7 | D:/USPTO Responses/Receipts/N417.PYMT (3).pdf | 4982720f8492db78 | 19/693,405 receipt, 30 May 2026 |
| 8 | D:/special/11-alzheimers-cure-discovery/LICENSE | e19b40f334497eb2 | Notice, exclusive property, no license granted |
| 9 | D:/special/11-alzheimers-cure-discovery/ALZHEIMERS_CURE_PATENT_APPLICATION.md | 52ba4e12febf0219 | Application text, 20 claims, four figures |
| 10 | D:/special/11-alzheimers-cure-discovery/findings/alzheimers_cure_discoveries.json | ef33a684d1184a3f | 14-record discovery data with scores and probabilities |
| 11 | D:/special/11-alzheimers-cure-discovery/_internal/run_alzheimers_discovery.py | 32f8486bfddc8775 | 451-line discovery script |
| 12 | D:/special/_inventory/descriptions-public/8457.md | 91a178c793863707 | Approved public wording, methodology, figures as defined |
| 13 | D:/manager/export_catalog_product_20260408_165843.csv | 1ec6bd9793cf5541 | Listing created 12 Mar 2026 with package download |
| 14 | D:/special/crione-static/site-inventory/inventory/item-8457/index.html | 87607f16610f9097 | Item page, purchase term, delivery line, notice |
| 15 | D:/manager/first-to-market/wayback_evidence.json | a0dde412013594b5 | Internet Archive first captures, 2010 to 2014 |
| 16 | D:/special/11-alzheimers-cure-discovery/IP_NOTICE.md | e02e8ba5eb0be489 | Open-research notice issued with the 12 Mar 2026 archive |
9. Notice Line
© 2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/441,975, 19/540,453 and 19/693,405.
cri-one.com/11-alzheimers-research-notes-discovery.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.Go to cart